Retinitis Pigmentosa
Surv Ophthalmol 33:137-177, Pagon,R.A., 1988
A Randomized Trial of Tenecteplase in Acute Central Retinal Artery Occlusion
NEJM 394:442-450, Ryan,S.J.,et al, 2026
Angioedema Following Tenecteplase for Acute Ischemic Stroke
Stroke 55:e242-e244, Dellabella,A.,et al, 2024
Angioedema After Use of Recombinant Tissue-Type Plasminogen Activators in Stroke
Stroke 55:2193-2197, Hutten,E., 2024
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Posterior Reversible Encephalopathy Syndrome
NEJM 388:2171-2178, Geocadin,R.G., 2023
Acute Toxic Leukoencephalopathy: Etiologies, Imaging Findings, and Outcomes in 101 Patients
AJNR 40:267-275, Ozutemiz, C.,et al, 2019
Restless Legs Syndrome Associated with Major Diseases
Neurol 86:1336-1343, Trenkwalder, C.,et al, 2016
The Lentiform Fork Sign
Neurol 84: e15, Fernandes, G.C.,et al, 2015
Synthetic Cannabinoid-Related Illnesses and Deaths
NEJM 373:103-107, Trecki, J.,et al, 2015
Microbleed Status and 3-Month Outcome After Intravenous Thrombolysis in 717 Patients with Acute Ischemic Stroke
Stroke 46:2458-2463,2403, Turc, G.,et al, 2015
Hemi Orolingual Angioedema after tPA Administration for Acute Ischemic Stroke
West J Emerg Med 16:175-177, Madden, B. & Chebl, R.B., 2015
Remote or Extraischemic Intracerebral Hemorrhage - An Uncommon Complication of Stroke Thrombolysis
Stroke 45:1657-1663, Mazya, M.V.,et al, 2014
Symptomatic Intracerebral Hemorrhage in Acute Ischemic Stroke After Thrombolysis With Intravenous Recombinant Tissue Plasminogen Activator
JAMA Neurol 81:1181-1185, Yaghi, S.,et al, 2014
Thrombolysis Despite Recent Stroke
Stroke 44:1736-1738, Alhazzaa, M.,et al, 2013
New Antithrombotic Drugs for Atrial Fibrillation: Caution is Needed
Lancet 379:e24, Bell,S.,et al, 2012
Clinicopathologic Conference,Necrotizing Noninflammatory Myopathy Consistent with Exposure to Statins
NEJM 36:944-954, Case 7-2012, 2012
Symptomatic Intracranial Hemorrhage after Stroke Thrombolysis: The SEDAN Score
Ann Neurol 71:634-641, Strbian,D.,et al, 2012
Lingual Hematoma After Thrombolytic Therapy
NEJM 364:e13, Vijayan,S. &Chase,A., 2011
Intravenous Thrombolytic Therapy for Acute Ischemic Stroke
NEJM 364:22, Wechsler, L.R., 2011
Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis
Neurol 77:341-348, Strbian, D.,et al, 2011
Rifaximin Treatment in Hepatic Encephalopathy
NEJM 362:1071-1081, 1140, Bass,N.M.,et al, 2010
Acute Hepatic Encephalopathy: Diffusion-Weighted and Fluid-Attenuated Inversion Recovery Findings, and Correlation With Plasma Ammonia Level and Clinical Outcome
AJNR 31:1471-1479, McKinney,A.M.,et al, 2010
Reduced Level of Consciousness from Baclofen in People with Low Kidney Function
BMJ 340:b4559, Su,W.,et al, 2009
Safety of Antiplatelet Therapy Prior to Intravenous Thrombolysis in Acute Ischemic Stroke
Arch Neurol 65:607-611,575, Uyttenboogaart,M.,et al, 2008
Thrombolysis with Alteplase 3 to 4.5 Hours After Acute Ischemic Stroke
NEJM 359:1317-1329,1393, Hacke,W.,et al, 2008
Symptomatic Intracerebral Hemorrhage and Recanalization After IV rt-PA: A Multicenter Study
Neurol 71:1304-1312, Saqqur,M.,et al, 2008
Facial Weakness in a Haemodialysis Patient
Lancet 369:714, Papadakis,M.,et al, 2007
The Safety of Hospital Stroke Care
Neurol 68:550-555,542, Holloway,R.G.,et al, 2007
Gadolinium-Based MR Contrast Agents and Nephrogenic Systemic Fibrosis
Radiology 242:647-649, Kuo,P.H.,et al, 2007
Leukoaraiosis and Intracerebral Hemorrhage After Thrombolysis in Acute Stroke
Neurol 68:1020-1024, Palumbo,V.,et al, 2007
Dystonia
NEJM 355:818-829, Tarsy,D. &Simon,D.K., 2006
Leukoaraiosis Is a Risk Factor for Symptomatic Intracerebral Hemorrhage After Thrombolysis for Acute Stroke
Stroke 37:2463-2466, Neumann-Haefelin,T.,et al, 2006
Continued Use of Zonisamide Following Development of Renal Calculi
Neurol 64:763-764, Richards, K.C., et al, 2005
Incidence of Contrast Nephropathy From Cerebral CT Angiography and CT Perfusion Imaging
Neurol 64:1805-1806, Josephson,S.A.,et al, 2005
Rhabdomyolysis: An Evaluation of 475 Hospitalized Patients
Medicine 84:377-385, Melli,G.,et al, 2005
Cefepime- and Cefixime-Induced Encephalopathy in a Patient With Normal Renal Function
Neurol 65:1840, Capparelli,F.J.,et al, 2005
The New Antiepileptic Drugs, Scientific Review
JAMA 291:605-614, LaRoche,S.M.&Helmers,S.L., 2004
Telemedicine for Acute Stroke
Stroke 34:725, LaMonte,M.P.,et al, 2003
Treatment of Wilson Disease With Ammonium Tetrathiomolybdate, III. Initial Therapy in a Total of 55 Neurologically Affected Patients and Follow-up With Zinc Therapy
Arch Neurol 60:379-385, Brewer,G.J.,et al, 2003
Hemi-orolingual Angioedema and ACE Inhibition After Alteplase Treatment of Stroke
Neurol 60:1525-1527,1403, Hill,M.D.,et al, 2003
Arterial Thrombosis Induced by IVIg and Its Treatment with tPA
Neurol 60:1825-1826,1736, Okuda,D.,et al, 2003
Severe Tacrolimus Leukoencephalopathy After Liver Transplantation
AJNR 24:2085-2088, Schuuring,J.,et al, 2003
Tissue Plasminogen Activator for Acute Ischemic Stroke in Clinical Practice
Stroke 34:2847-2850, Graham,G.D., 2003
Predictors of Hemorrhagic Transformation in Patients Receiving Intra-Arterial Thrombolysis
Stroke 33:717-724, Kidwell,C.S.,et al, 2002
Thrombolytic Therapy Within 3 to 6 Hours After Onset of Ischemic Stroke
Stroke 33:1437-1441, Ringleb,P.A.,et al, 2002
Protocol Violations in Community-Based rTPA Stroke Treatment Are Associated with Symptomatic Intracerebral Hemorrhage
Stroke 32:12-16, Lopez-Yunez,A.M.,et al, 2001
Risk Factors for Sever Hemorrhagic Transformation in Ischemic Stroke Patients Treated with Recombinant Tissue Plasminogen Activator
Stroke 32:438-441, Larrue,V.,et al, 2001
Safety of Intra-Arterial Thrombolysis in the Postoperative Period
Stroke 32:1365-1369, Chalela,J.A.,et al, 2001